SWX:LONNLife Sciences
Lonza Group (SWX:LONN) Expands Biologics And ADC Push As Undervalued Narrative Builds
Lonza Group (SWX:LONN) has been active on several fronts, with fresh agreements covering biologics manufacturing, central nervous system drug delivery research and antibody drug conjugate payload production capacity at its Visp site.
See our latest analysis for Lonza Group.
Lonza Group’s recent series of CNS partnerships, biologics expansions and ADC capacity investments has coincided with building momentum, with a 30-day share price return of 18.3% and a 1-year total shareholder return of...